JP4098985B2 - テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法 - Google Patents

テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法 Download PDF

Info

Publication number
JP4098985B2
JP4098985B2 JP2001585813A JP2001585813A JP4098985B2 JP 4098985 B2 JP4098985 B2 JP 4098985B2 JP 2001585813 A JP2001585813 A JP 2001585813A JP 2001585813 A JP2001585813 A JP 2001585813A JP 4098985 B2 JP4098985 B2 JP 4098985B2
Authority
JP
Japan
Prior art keywords
tetrahydropiperine
piperine
test
skin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001585813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534295A (ja
JP2003534295A5 (https=
Inventor
ムハムド マジェード
ウラジミール バドマエフ
クマー ラジンダー バミイ
サバラクシミ プラカシ
サンカラン ナタラヤン
Original Assignee
サビンサ コーポレーション
サミ ラブズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サビンサ コーポレーション, サミ ラブズ リミテッド filed Critical サビンサ コーポレーション
Publication of JP2003534295A publication Critical patent/JP2003534295A/ja
Publication of JP2003534295A5 publication Critical patent/JP2003534295A5/ja
Application granted granted Critical
Publication of JP4098985B2 publication Critical patent/JP4098985B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fodder In General (AREA)
JP2001585813A 2000-05-19 2001-05-21 テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法 Expired - Lifetime JP4098985B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20524500P 2000-05-19 2000-05-19
US60/205,245 2000-05-19
US27797901P 2001-03-23 2001-03-23
US60/277,979 2001-03-23
PCT/US2001/016070 WO2001089571A2 (en) 2000-05-19 2001-05-21 Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives

Publications (3)

Publication Number Publication Date
JP2003534295A JP2003534295A (ja) 2003-11-18
JP2003534295A5 JP2003534295A5 (https=) 2007-04-19
JP4098985B2 true JP4098985B2 (ja) 2008-06-11

Family

ID=26900240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585813A Expired - Lifetime JP4098985B2 (ja) 2000-05-19 2001-05-21 テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法

Country Status (6)

Country Link
US (1) US6849645B2 (https=)
JP (1) JP4098985B2 (https=)
AU (1) AU2001278849A1 (https=)
DE (2) DE10196213B4 (https=)
GB (1) GB2380675B (https=)
WO (1) WO2001089571A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105576B2 (en) * 2002-04-24 2006-09-12 Research Development Foundation Synergistic effects of nuclear transcription factor NF-κB inhibitors and anti-neoplastic agents
WO2004000229A2 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
WO2004067018A1 (en) * 2003-01-30 2004-08-12 Council Of Scientific And Industrial Research Bioavailability enhancing activity of carum carvi extracts and fractions thereof
AU2004320907A1 (en) 2003-08-26 2006-04-13 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
WO2006121421A2 (en) * 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060130675A1 (en) * 2004-11-30 2006-06-22 Crawford David S Transdermal nutritional supplement delivery patch
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
US20070237735A1 (en) * 2006-03-31 2007-10-11 Laboratoires Dermo-Cosmetik Inc. Anti-aging composition, kit and method of use
US20080138417A1 (en) * 2006-11-22 2008-06-12 Charles Grigsby Topical Composition And Method Of Forming
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US10898537B2 (en) 2015-07-31 2021-01-26 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
KR102655937B1 (ko) * 2016-09-27 2024-04-11 (주)아모레퍼시픽 코스모페린을 포함하는 항스트레스 조성물
AU2017343886B2 (en) * 2016-10-14 2023-07-06 Cipla Limited Pharmaceutical compositions comprising rifaximin
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US20200268761A1 (en) * 2017-09-19 2020-08-27 Cipla Limited Compositions comprising ibrutinib and an alkaloid having enhanced bioavailability
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
US20200179362A1 (en) * 2018-12-05 2020-06-11 James E. Beecham Dietary supplement comprising glucuronidation inhibition assist for healthful daily synergy of anti-inflammation, cellular anti-oxidant boost, cellular protein clean-up boost
JP7163261B2 (ja) * 2019-09-27 2022-10-31 富士フイルム株式会社 水中油型乳化組成物、及び皮膚外用剤
CN115670998A (zh) * 2022-11-18 2023-02-03 广州澳莱娜生物科技有限公司 一种祛痘控油亮肤组合物及其制备方法
CN115813822B (zh) * 2022-12-16 2024-06-25 厦门海尼新创生物科技有限公司 一种高效祛痘组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT398259B (de) * 1982-09-30 1994-11-25 Dainippon Jochugiku Kk Thermischer räucherapparat für ein chemisches präparat
DE4392300T1 (de) * 1992-05-21 1995-12-07 Jeff J Staggs Therapeutische Gebräuche von beißenden Pflanzen und Ihre Verwandten Zusammensetzungen
CA2098889A1 (en) * 1992-07-06 1994-01-07 Takashi Chinuki Slow-releasing medicated resin moldings and process for producing the same
IN176897B (https=) * 1993-10-29 1996-09-28 Cadila Lab Ltd
US5439891A (en) * 1993-10-29 1995-08-08 Kapil; Randhir S. Process for preparation of pharmaceutical composition with enhanced activity for treatment of tuberculosis and leprosy
JP2946452B2 (ja) * 1994-11-04 1999-09-06 カディラ ラボラトリーズ リミテッド ピペリンを含む組成物
US5744161A (en) * 1995-02-24 1998-04-28 Sabinsa Corporation Use of piperine as a bioavailability enhancer
EP0935964A1 (en) * 1998-02-12 1999-08-18 Panacea Biotec Limited Pharmaceutical compositions containing NSAIDs and piperine
GB9815177D0 (en) * 1998-07-13 1998-09-09 King S College London Treatment of skin disorders

Also Published As

Publication number Publication date
GB2380675A (en) 2003-04-16
WO2001089571A3 (en) 2002-03-07
DE10196213B4 (de) 2020-12-17
US20020058695A1 (en) 2002-05-16
GB0229561D0 (en) 2003-01-22
US6849645B2 (en) 2005-02-01
AU2001278849A1 (en) 2001-12-03
JP2003534295A (ja) 2003-11-18
GB2380675B (en) 2004-11-03
DE10196213T1 (de) 2003-04-30
WO2001089571A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
JP4098985B2 (ja) テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法
JP7374951B2 (ja) 安定なカンナビノイド製剤
Azeem et al. Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation
CN101790370B (zh) 一种新的双氯芬酸非水局部用溶液及其制备方法
CN115038430B (zh) 自微乳化的多种可递送物的系统
KR20130129953A (ko) 난용성 화합물의 용해도를 증가시키는 방법과 이와 같은 화합물의 제형을 제조하는 방법 및 사용하는 방법
KR20170008311A (ko) 안정한 카나비노이드 제형
WO1998008966A1 (en) Loxoprofen-containing preparation for external use
JP2004515453A (ja) 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
ES2886673T3 (es) Un proceso para la preparación de curcumina blanca biodisponible, una mezcla única de curcuminoides hidrogenados
US20160256513A1 (en) Synergized turmeric
CA2994331C (en) Transdermal formulations for delivery of capsaicinoids
Marquele-Oliveira et al. Physicochemical characterization by AFM, FT-IR and DSC and biological assays of a promising antileishmania delivery system loaded with a natural Brazilian product
JP7758770B2 (ja) 基底細胞がんおよび神経膠芽腫を治療する方法
US10369170B1 (en) Methods of treating basal cell carcinoma and glioblastoma
Sarangamath et al. Invasomes: A vesicular carrier for transdermal delivery
Tufail et al. Formulation and characterization of herbosome: A review
JP5897299B2 (ja) ローション剤
Mazzacuva et al. Curcumin and Neglected Infectious Diseases
EP4351506B1 (en) Lipid crystalline compositions with enhanced stability for topical delivery of active agent combinations
CN115209890B (zh) 抑制促炎基因表达的紫草素、芳基萘木酚素以及包含它们的药物组合物
FR3004651A1 (fr) Composition pharmaceutique ou dietetique ayant pour objet l augmentation du passage des xenobiotiques des medicaments et des nutriments au travers des barrieres biologiques
US20240207289A1 (en) Method to identify and alleviate the symptoms of parkinsonism/parkinson’s disease
Sarker et al. Formulation and Delivery of Mitragynine: A Mini Review
YEN RESEARC'H AND DEVELOPMENT OF SELF EMULSlFYING DRUG DELIVERY SYSTEM (SEDDS) FOR ENHANCED BIOAVAILABILITY OF CURCUMIN

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061117

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20061117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070228

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20070228

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20070329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080314

R150 Certificate of patent or registration of utility model

Ref document number: 4098985

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110321

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110321

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130321

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140321

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term